Neovasculgen for interstitial cystitis with Hunner's lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized Phase 2/3 study compares Neovasculgen with placebo in women aged 18–65 who have interstitial cystitis with confirmed Hunner's lesions and symptoms for at least 12 months. Participants receive Neovasculgen or placebo in addition to standard lesion management and are followed for safety, bladder scarring, bladder volume, and symptoms. Outcomes are measured with cystoscopy, voiding diaries, questionnaires, and imaging or urodynamic measures as appropriate. The goal is to see if Neovasculgen reduces cicatricial changes after lesion treatment and helps preserve bladder capacity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent prior to any study-related procedures.
2. Women aged 18 to 65 years, inclusive.
3. A confirmed diagnosis of painful bladder syndrome/interstitial cystitis, characterized by pelvic pain associated with filling or emptying the bladder, frequent urination day and night, with symptoms lasting at least 12 months, with the exclusion of a urinary tract infection or other disease that could cause such symptoms.
4. The presence of Hunner's lesions of the bladder during cystoscopy with hydrobougienage of the bladder (2 minutes, 80 cm H2O).
5. A glycated hemoglobin level within the normal range for the patient's age group.
6. Ability to comply with all study requirements, in the opinion of the investigator, including regularly keeping a voiding diary, completing questionnaires, and attending all scheduled study visits.
7. Women who are of childbearing potential must have negative pregnancy test results and must use reliable contraception throughout their participation in the study.

Exclusion Criteria:

1. Any condition that prevents intravesical administration of medications.
2. Received medication or non-medication therapy, including physical therapy, for BPS/IC within 1 month prior to study inclusion.
3. Instillation of any pharmacological agent into the bladder less than 1 month prior to screening.
4. History of chronic drug or alcohol abuse.
5. Pregnant women, planning to become pregnant during the study, or currently breastfeeding.
6. Any other conditions associated with pelvic pain, except for PBS.
7. Pelvic surgery less than 6 months prior to the study.
8. Any intravesical procedures, except for diagnostic cystoscopy, less than 3 months prior to screening.
9. History of allergy or intolerance to the anesthetic or antibiotics that the investigator intends to use during the study.
10. Inability to discontinue anticoagulant/antiplatelet medications at least 5 days prior to each investigational drug administration and resume them on the 4th day after each investigational drug administration (low molecular weight heparin may be used for 3 days after investigational drug administration).
11. Diseases of the urinary tract/bladder (neoplasms, tuberculous and bacterial cystitis, urolithiasis, radiation injury, urethral diverticulum, neurogenic dysfunction of the lower urinary tract) and female genital organs (neoplasms, vaginitis, genital infections).
12. Other conditions that, in the opinion of the research physician, could become an objective obstacle to the patient's participation in the study and/or create additional risks for the patient.
13. A history of intravesical botulinum therapy performed within the last 12 months prior to inclusion in this study.
14. Bladder capacity under anesthesia less than 150 ml.
15. Residual urine volume greater than 50 ml.

Where it's running

• Botkin Hospital
  Moscow, Russia Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aerobic Exercise and Massage for Painful Bladder Syndrome in Women

  This study tests whether adding aerobic exercise and connective tissue massage to patient education helps reduce bladder pain and improve symptoms for women with bladder pain syndrome.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07839689

• Comparing Botox injections to conservative management for female sexual function in bladder pain syndrome

  This study tests whether Botox injections can improve sexual function in women with bladder pain syndrome better than standard treatment options.

  Recruiting Walter Reed National Military Medical Center · Bethesda, Maryland · NCT06729151

• Evaluating a catheter-free method for bladder medication delivery

  This study is testing a new way to deliver bladder medication without a catheter to see if it’s more comfortable and safer for people with conditions like interstitial cystitis and recurrent urinary tract infections.

  Recruiting at 2 sites Jahn Ferenc South Pest Teaching Hospital · Budapest and 1 other locations · NCT06719232

• Treatment of bladder pain using VNX001

  This study is testing a new treatment called VNX001 to see if it can help people with moderate to severe bladder pain feel better.

  Recruiting at 2 sites Phase 2 Vaneltix Pharma, Inc. · Tucson, Arizona and 4 other locations · NCT06394830

• Using Botox to treat overactive bladder while preventing urinary tract infections

  This study is testing if Botox injections for overactive bladder can be safely combined with a specific antibiotic to help prevent urinary tract infections in women.

  Recruiting Phase 4 Walter Reed National Military Medical Center · Bethesda, Maryland · NCT06387329

• Acupuncture for treating bladder pain syndrome in women

  This study is testing if acupuncture, along with some behavior changes, can help women with bladder pain syndrome feel better when other treatments haven't worked.

  Recruiting University Hospitals Cleveland Medical Center · Cleveland, Ohio · NCT06366269

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.